Stockscreener 앱 받기
0.89
0.00%
0.00
시장 영업 전:
.88
-0.01
-1.12%
전일 마감가:
$0.89
열려 있는:
$0.8995
하루 거래량:
152.20K
Relative Volume:
0.45
시가총액:
$26.43M
수익:
-
순이익/손실:
$-10.21M
주가수익비율:
-1.5235
EPS:
-0.5842
순현금흐름:
-
1주 성능:
-23.93%
1개월 성능:
-5.33%
6개월 성능:
-62.61%
1년 성능:
-4.30%
1일 변동 폭
$0.86
$0.8995
1주일 범위
$0.86
$1.0999
52주 변동 폭
$0.81
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
NRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.89 | 26.43M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell - Defense World
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - setenews.com
NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView — Track All Markets
NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView — Track All Markets
NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) locks RoAD Phase 2 Alzheimer’s trial database, eyes Q1 2026 data - Stock Titan
NeuroSense completes data collection for Alzheimer’s trial - MSN
Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser
How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq
NeuroSense Therapeutics LtdResuming regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis - marketscreener.com
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks
Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView
NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan
Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser
How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser
NeuroSense Therapeutics (NRSN) Stock Analysis Report | Financials & Insights - Benzinga
What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser
Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ
Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt
Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn
NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World
NeuroSense Gains FDA Approval for Phase 3 ALS Trial - MSN
Prepare Yourself for Liftoff: NeuroSense Therapeutics Ltd (NRSN) - setenews.com
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense receives FDA clearance to initiate pivotal phase 3 trial for PrimeC in ALS - marketscreener.com
NeuroSense Therapeutics (NRSN) Maintains 'Buy' Rating and $14 Ta - GuruFocus
NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS - marketscreener.com
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - Barchart.com
NeuroSense Therapeutics Ltd. (NRSN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can NeuroSense Therapeutics Ltd. (H1Z) stock ride next bull market cyclePortfolio Value Summary & AI Forecasted Stock Moves - newser.com
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - TipRanks
Can NeuroSense Therapeutics Ltd. stock hit analyst price targetsQuarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - newser.com
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan
Is NeuroSense Therapeutics Ltd. (H1Z) stock a safe buy pre earningsWatch List & Consistent Growth Equity Picks - newser.com
Will NeuroSense Therapeutics Ltd. (H1Z) stock beat revenue estimatesDip Buying & Free Reliable Trade Execution Plans - newser.com
How strong dollar benefits NeuroSense Therapeutics Ltd. (H1Z) stockJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com
Using RSI to spot recovery in NeuroSense Therapeutics Ltd.IPO Watch & Weekly Top Stock Performers List - newser.com
What risks investors should watch in NeuroSense Therapeutics Ltd. Equity Warrant stockQuarterly Portfolio Review & Low Volatility Stock Suggestions - newser.com
Why NeuroSense Therapeutics Ltd. stock is in analyst buy zoneJuly 2025 Retail & Free Safe Entry Trade Signal Reports - newser.com
Key metrics from NeuroSense Therapeutics Ltd. Equity Warrant’s quarterly data2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
What sentiment indicators say about NeuroSense Therapeutics Ltd. stockQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com
Is NeuroSense Therapeutics Ltd. stock a bargain at current levels - newser.com
Will NeuroSense Therapeutics Ltd. (H1Z) stock sustain uptrend momentumWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Neurosense Therapeutics Ltd (NRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):